- Announced the submission of bids on 5 significant US Federal Government Requests For Proposal to test in excess of 50,000 Federal employees using the Company’s KAI Medical COVID-19 Saliva Test
- KAI Saliva is an FDA EUA authorized Saliva COVID-19 RT-PCR Test
- In addition, RPF bids for over 10,000 of the approximate 50,000 employees are for ongoing testing, representing potential for significant recurring test revenues.
KAI Lab R&D, Development And Delivery Of KAI Saliva At-Home Test Kit Program, Along With Tripling Of KAI Lab Facility, Proves Valuable By Providing Empower With Ability To Bid and Accommodate Successful RFPs
VANCOUVER, BC / March 24, 2021 / EMPOWER CLINICS INC. (CBDT:CSE) (8EC:Frankfurt) (EPWCF:OTCQB) (“Empower” or the “Company“) an integrated healthcare company – serving patients through medical centers, telemedicine platforms and a high complexity medical diagnostics laboratory processing thousands of COVID-19 specimens, is pleased to announce the submission of bids on 5 significant US Federal Government Requests For Proposal (“RFP” or “RFPs”) to test in excess of 50,000 Federal employees using the Company’s KAI Medical COVID-19 Saliva Test (“KAI Saliva”). KAI Saliva is an FDA EUA authorized Saliva COVID-19 RT-PCR Test.
In addition, RPF bids for over 10,000 of the approximate 50,000 employees are for ongoing testing, representing potential for significant recurring test revenues.
RFP BIDS INCLUDE FDA ITSELF, AIRPORT, SCHOOLS AND OTHER FACILITIES ACROSS THE COUNTRY
Empower has submitted US Government RFP bids for the following groups:
1. FDA – Food & Drug Administration
- All Employees and contractors nationwide
- Kai Saliva at-home test kit program
- In excess of 38,000 kits required
2. Hanover County, Virginia Government
- Public Schools
- Regional Jail
- Regional Library
- 5,000 employees – Ongoing Testing
- Kai Saliva at-home test kit program
- Rapid antigen testing kits
3. Scranton, Pennsylvania Airport
Onsite testing facility for:
- RT-PCR testing
- Rapid Testing
- Saliva RT-PCR testing
- Ongoing testing
4. Alameda County, California
- 3,100 employees and contractors – ongoing testing
- Kai Saliva at-home test kit program
5. Durham County, North Carolina
- 2,000 employees and contractors – ongoing testing
- Kai Saliva at-home test kit program
RFP’S STEM FROM BIDEN ADMINISTRATION TO INVEST MORE THAN $12 BILLION TO EXPAND COVID-19 TESTING
These measures are part of President Biden’s strategy to increase COVID-19 testing nationwide as vaccinations increase.
As part of President Biden’s National Strategy for the COVID-19 Response and Pandemic Preparedness, the U.S. Department of Health and Human Services (HHS) will invest $10 billion from the American Rescue Plan to ramp up screening testing to help schools reopen, $2.25 billion to scale up testing in underserved populations, and provide new guidance on asymptomatic screening testing in schools, workplaces, and congregate settings.
Empower Clinics is ideally positioned with the right products.
KAI LAB AND KAI SALIVA COVID-19 PCR TEST COMPETITIVE ADVANTAGES IN RFP BIDS
Empower’s KAI Medical COVID-19 Saliva Test (“KAI Saliva”) is an FDA EUA authorized Saliva COVID-19 RT-PCR Test that includes the following meaningful competitive advantages
- KAI Salvia is an at-home based, self-administered COVID-19 RT-PCR saliva test kit that is easily accessed and self-administered. Visit www.kaitests.com
- KAI Saliva provides travelers, both foreign and domestic with a simple, fully compliant method to obtain an RT-PCR test and test result prior to arriving or coming back into the United States or arriving in other countries that have strict executive travel orders.
- KAI Saliva can provide major airlines and the tourism sector with the ability to provide solutions for travelers by making a KAI Saliva test as part of the ticketing purchase, the check-in process, in a kiosk, or on an e-commerce website.
- As a result of continued rapid growth in 2021, Empower announced “Doubling KAI Medical Laboratory In Anticipation Of Test Volumes By End Of Q1.” The Company then revised this planned expansion upwards on February 16th when it announced “KAI Laboratory Now Tripling in Size in Anticipation of Test Volumes by End of Q1.”
As a result of these competitive advantages, Empower believes the integrated solution of KAI Lab and KAI Saliva makes for a very strong offering.
“Our decision to triple the size of Kai Labs was in anticipation of positioning Kai Labs for growth and to be able bid on many significant U.S. Government contracts that are being awarded” said Steven McAuley, Chairman & CEO. “With investment in R&D and having substantial working capital available, I believe Kai Labs is deserving of national attention and has as a real opportunity to win these type of bids. Our new Kai Saliva test kit is in high demand and we are seeing more and more bids specifically requesting saliva-based COVID-19 testing products.”
This press release is available on the Empower Clinics Verified Forum on AGORACOM for shareholder discussion, questions and engagement with management https://agoracom.com/ir/EmpowerClinics
ABOUT EMPOWER:
Empower is an integrated healthcare company that provides body and mind wellness for patients through its clinics, with digital and telemedicine care, and world-class medical diagnostics laboratories. Supported by an experienced leadership team, Empower is aggressively growing its clinical and digital presence across North America. Our Health & Wellness and Diagnostics & Technology business units are positioned to positively impact the integrated health of our patients, while simultaneously providing long term value for our shareholders.
ON BEHALF OF THE BOARD OF DIRECTORS:
Steven McAuley
Chief Executive Officer
CONTACTS:
Investors:
Steven McAuley CEO
[email protected]
604-789-2146
Investors:
Tamara Mason
Business Development & Communications
[email protected]
416-671-5617
DISCLAIMER FOR FORWARD-LOOKING STATEMENTS
This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include, but are not limited to, statements regarding: the expected benefits to the Company and its shareholders as a result of the acquisition of Kai Medical Laboratory; the transaction terms; the expected number of clinics and patients following the closing; the future potential success of Kai Medical Laboratory, Sun Valley’s franchise model; launch of new healthcare centers and the occurrence thereof; that the Company can bring healthcare to millions of Canadians; that new healthcare services can be added and that the Company will be positioned to be a market- leading service provider for complex patient requirements in 2020 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that Kai Medical Laboratory will successfully win any US Government RFP; that the MedX Health pilot program will be successful; that Empower will place the MedX Health teledermatology product in health centers in North America; that the Company’s products may not work as expected; that the Company may not be able to expand COVID-19 testing; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; that the Company will be able to commence and/or complete build-outs and tenants improvements for Canadian clinics or Kai Medical Laboratory expansion inn 2Q 2021; that general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed transaction; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.
